Michelle L Gordon

List of Publications by Year
in descending order

46 papers	1,387 citations	394421 19 h-index	345221 36 g-index
46 all docs	46 docs citations	46 times ranked	2168 citing authors

#	Article	IF	Citations
1	Review of genome sequencing technologies in molecular characterization of influenza A viruses in swine. Journal of Veterinary Diagnostic Investigation, 2022, 34, 177-189.	1.1	7
2	A systematic review of influenza A virus prevalence and transmission dynamics in backyard swine populations globally. Porcine Health Management, 2022, 8, 10.	2.6	13
3	An overview of influenza A virus genes, protein functions, and replication cycle highlighting important updates. Virus Genes, 2022, 58, 255-269.	1.6	22
4	Vulnerable targets in HIV-1 Pol for attenuation-based vaccine design. Virology, 2021, 554, 1-8.	2.4	1
5	Modulatory influences of antiviral bioactive compounds on cell viability, mRNA and protein expression of cytochrome P450 3A4 and P-glycoprotein in HepG2 and HEK293 cells. Bioorganic Chemistry, 2021, 107, 104573.	4.1	5
6	Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch. Biomolecules, 2021, 11, 489.	4.0	3
7	Recombinant expression of HIV-1 protease using soluble fusion tags in Escherichia coli: A vital tool for functional characterization of HIV-1 protease. Virus Research, 2021, 295, 198289.	2.2	3
8	Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors. European Journal of Medicinal Chemistry, 2021, 217, 113330.	5.5	29
9	HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. International Journal of Antimicrobial Agents, 2021, 57, 106343.	2.5	47
10	Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease. Journal of Biomolecular Structure and Dynamics, 2021, , 1-10.	3.5	2
11	Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients. Journal of Biomolecular Structure and Dynamics, 2021, , 1-11.	3.5	1
12	Deciphering transmission dynamics and spillover of avian influenza viruses from avian species to swine populations globally. Virus Genes, 2021, 57, 541-555.	1.6	13
13	Molecular dynamic mechanism(s) of inhibition of bioactive antiviral phytochemical compounds targeting cytochrome P450 3A4 and P-glycoprotein. Journal of Biomolecular Structure and Dynamics, 2020, , 1-11.	3.5	13
14	A Systematic Review Analyzing the Prevalence and Circulation of Influenza Viruses in Swine Population Worldwide. Pathogens, 2020, 9, 355.	2.8	32
15	The pharmacokinetic properties of HIV-1 protease inhibitors: A computational perspective on herbal phytochemicals. Heliyon, 2019, 5, e02565.	3.2	38
16	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000â€“2016: A Pooled Sequence Analysis. EClinicalMedicine, 2019, 9, 26-34.	7.1	51
17	Gag-protease coevolution shapes the outcome of lopinavir-inclusive treatment regimens in chronically infected HIV-1 subtype C patients. Bioinformatics, 2019, 35, 3219-3223.	4.1	6
18	Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads compared to other HIV-1-associated meningitides. PLoS ONE, 2018, 13, e0192060.	2.5	11

#	Article	IF	Citations
19	Candidate gene polymorphisms related to lipid metabolism in Asian Indians living in Durban, South Africa. Indian Journal of Medical Research, 2018, 148, 169.	1.0	4
20	Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals. Viruses, 2017, 9, 330.	3.3	4
21	HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 384-389.	2.1	8
22	Treatment options after virological failure of first-line tenofovir-based regimens in South Africa. Aids, 2016, 30, 1137-1140.	2.2	15
23	Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. International Journal of Antimicrobial Agents, 2016, 48, 158-162.	2.5	16
24	Analysis of Dominant HIV Quasispecies Suggests Independent Viral Evolution Within Spinal Granulomas Coinfected with Mycobacterium tuberculosis and HIV-1 Subtype C. AIDS Research and Human Retroviruses, 2016, 32, 262-270.	1.1	6
25	A postâ€partum singleâ€dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving preâ€partum ZDV and intrapartum singleâ€dose nevirapine to prevent motherâ€toâ€child HIVâ€1 transmission. Journal of Medical Virology, 2015, 87, 1662-1667.	5.0	1
26	Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe. PLoS ONE, 2015, 10, e0144057.	2.5	50
27	Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries. AIDS Reviews, 2014, 16, 187-98.	1.0	8
28	Early Warning Indicators for First-Line Virologic Failure Independent of Adherence Measures in a South African Urban Clinic. AIDS Patient Care and STDs, 2013, 27, 657-668.	2.5	47
29	Drug Resistance Pattern of HIV Type 1 Isolates Sampled in 2007 from Therapy-Naive Pregnant Women in North-Central Nigeria. AIDS Research and Human Retroviruses, 2012, 28, 115-118.	1.1	17
30	Drug Resistance and Coreceptor Usage in HIV Type 1 Subtype C-Infected Children Initiating or Failing Highly Active Antiretroviral Therapy in South Africa. AIDS Research and Human Retroviruses, 2012, 28, 324-332.	1.1	19
31	High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. Aids, 2012, 26, 1679-1684.	2.2	76
32	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 2012, 433, 410-420.	2.4	12
33	Genetic Characteristics, Coreceptor Usage Potential and Evolution of Nigerian HIV-1 Subtype G and CRF02_AG Isolates. PLoS ONE, 2011, 6, e17865.	2.5	17
34	Resistance to antiretroviral drugs in newly diagnosed, young treatmentâ€naÃ¯ve HIVâ€positive pregnant women in the province of KwaZuluâ€Natal, South Africa. Journal of Medical Virology, 2011, 83, 1508-1513.	5.0	21
35	Outcomes after virologic failure of first-line ART in South Africa. Aids, 2010, 24, 1007-1012.	2.2	59
36	HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression. Retrovirology, 2010, 7, 92.	2.0	15

#	Article	IF	Citations
37	Prevalence of HIVâ€1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa. Clinical Infectious Diseases, 2008, 46, 1589-1597.	5.8	226
38	Development of Dual-class Antiretroviral Drug Resistance in a Child Coinfected with HIV and Tuberculosis: A Case Report from KwaZulu-Natal, South Africa. Journal of Tropical Pediatrics, 2007, 55, 60-62.	1.5	1
39	Tracing the origin of Brazilian HTLV-1 as determined by analysis of host and viral genes. Aids, 2006, 20, 780-782.	2.2	24
40	BioAfrica's HIV-1 proteomics resource: combining protein data with bioinformatics tools. Retrovirology, 2005, 2, 18.	2.0	18
41	Mapping Sites of Positive Selection and Amino Acid Diversification in the HIV Genome. Genetics, 2004, 167, 1047-1058.	2.9	49
42	Inner shell excitation of glycine, glycyl-glycine, alanine and phenylalanine. Journal of Electron Spectroscopy and Related Phenomena, 2004, 137-140, 795-799.	1.7	76
43	MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clinical Pharmacology and Therapeutics, 2003, 74, 195-196.	4.7	19
44	Inner-Shell Excitation Spectroscopy of the Peptide Bond:â€‰ Comparison of the C 1s, N 1s, and O 1s Spectra of Glycine, Glycyl-Glycine, and Glycyl-Glycyl-Glycine. Journal of Physical Chemistry A, 2003, 107, 6144-6159.	2.5	162
45	Variability at Human Immunodeficiency Virus Type 1 Subtype C Protease Cleavage Sites: an Indication of Viral Fitness?. Journal of Virology, 2003, 77, 9422-9430.	3.4	60
46	Molecular Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Viruses from KwaZulu-Natal, South Africa: Implications for Vaccine and Antiretroviral Control Strategies. Journal of Virology, 2003, 77, 2587-2599.	3.4	60